Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea

• Status: Terminated
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

In this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in thyroid surgical female population. Two hundred and forty six female patients receiving general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5 mg or placebo before emergence.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Bordeaux
• Collaborator: Prostrakan Pharmaceuticals
• Treatments: Droperidol

Criteria

Inclusion Criteria:

• Female

• More than 18 years old

• Patients scheduled for thyroid surgery

• Simplified Apfel score ≥ 2

• ASA score : 1-2

• Informed consent obtained from the patient

• Women able to procreate must have a reliable contraceptive method

Exclusion Criteria:

• Age < 18 years old

• Male

• Obesity

• Has a severe depressive syndrome

• Pregnancy women

• Trouble with cardiac rate

• Alcoholism

• Contra-indication for Droperidol prescription